WEKO3
アイテム
A head-to-head comparison between [11C]PBB3 and [18F]PM-PBB3 in patients with AD and non-AD tauopathy
https://repo.qst.go.jp/records/66599
https://repo.qst.go.jp/records/6659934e5f115-6f4c-4cc4-933d-c6350ff0a436
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-01-22 | |||||
| タイトル | ||||||
| タイトル | A head-to-head comparison between [11C]PBB3 and [18F]PM-PBB3 in patients with AD and non-AD tauopathy | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
久保田, 学
× 久保田, 学× 島田, 斉× 互, 健二× 北村, 聡一郎× 小野, 麻衣子× 木村, 泰之× 市瀬, 正則× 篠遠, 仁× 高畑, 圭輔× 山本, 保天× 佐野, 康徳× 関, 千江× Tempest, Paul× Jang, Ming-Kuei× Seibyl, John× Barret, Olivier× Alagille, David× Marek, Kenneth× 張, 明栄× 須原, 哲也× 樋口, 真人× 久保田 学× 島田 斉× 互 健二× 北村 聡一郎× 小野 麻衣子× 木村 泰之× 市瀬 正則× 篠遠 仁× 高畑 圭輔× 山本 保天× 佐野 康徳× 関 千江× 張 明栄× 須原 哲也× 樋口 真人 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: We recently developed a novel fluorinated tau PET ligand, [18F]PM-PBB3, to improve characteristics of [11C]PBB3. Our preclinical evidence suggested that [18F]PM-PBB3 could capture tau deposits in living brains with high contrast and favorable kinetics. Here, we conducted a head-to-head comparison between PET data obtained using [11C]PBB3 and [18F]PM-PBB3 in patients with Alzheimer’s disease (AD) and non-AD tauopathy. Methods: Patients with AD and progressive supranuclear palsy (PSP), and healthy controls (HCs) underwent three PET scans with [11C]PiB, [11C]PBB3, and [18F]PM-PBB3. In the scan with [18F]PM-PBB3, arterial blood sampling was performed to determine binding potential (BPND) of the radioligand based on a compartment model. We also calculated BPND by a reference tissue model and standardized uptake value ratio (SUVR) using the cerebellum gray matter as reference. These estimates were compared to SUVR values of [11C]PBB3 in each subject. Results: The BPND values of [18F]PM-PBB3 by a reference tissue model and SUVR were in good agreement with those by a compartment model. Compared to [11C]PBB3, the peak brain radioactivity and contrast for tau lesions yielded by [18F]PM-PBB3 were almost double of those produced by [11C]PBB3. Unlike [11C]PBB3, [18F]PM-PBB3 showed minimal off-site binding in the brain parenchyma including the striatum. Binding of [18F]PM-PBB3 in the brainstem was not evident in AD patients and HCs, but was prominent in PSP patients, resulting in a vivid contrast between PSP patients and the other subjects. Conclusion: The current results indicate that [18F]PM-PBB3 would be a promising PET ligand to quantify tau accumulation in AD and PSP patients with suitable kinetics and high contrast. The wide dynamic range and minimal parenchymal off-site binding of [18F]PM-PBB3 would allow its application to differentiations among AD, non-AD tauopathies and HC by both visual inspection and quantitative assessments on an individual basis in a clinical workup. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 12th Human Amyloid Imaging | |||||
| 発表年月日 | ||||||
| 日付 | 2018-01-17 | |||||
| 日付タイプ | Issued | |||||
